SOLON, Ohio– Pioneering the frontier of super-pulsed laser technology, Multi Radiance Medical highlights the impact of FibroLux Therapeutic Laser, one of the first and only FDA-cleared therapeutic lasers designed to alleviate pain specifically for individuals battling Fibromyalgia Syndrome. Cleared by the FDA in September 2022 and officially launched late 2023, FibroLux represents a significant milestone in addressing the challenges of Fibromyalgia.
Fibromyalgia affects an estimated 5 million to 8 million Americans and is known for causing chronic widespread pain and tenderness, with limited treatment options, often with adverse side effects. FibroLux Therapy Laser emerges as a cutting-edge, non-invasive, and drug-free solution offering rapid and effective relief by using light energy, in the form of photons to penetrate cells, increasing blood circulation and shutting down pain signals. Clinically proven with minimal side effects, FibroLux is a portable, handheld device that precisely targets 18 tender points, delivering immediate relief in just 2 minutes per point, and an average treatment duration of 6-10 minutes.
“FibroLux, as one of the first medical devices cleared for fibromyalgia, represents a transformative paradigm shift, providing life-changing relief without side effects,” said Max Kanarsky, President and CEO of Multi Radiance Medical. “This laser technology empowers individuals to perform daily activities free from the burden of pain, offering a beacon of hope for those handicapped by fibromyalgia. Recent positive reception at medical conferences underscores the importance of raising awareness among both patients and clinicians.”
FibroLux has exhibited remarkable outcomes in clinical trials, boasting a 52% reduction in tender points, a 53% decrease in pain, and a 45% enhancement in Fibromyalgia Impact Questionnaire scores. In the ground-breaking peer-reviewed study, “Photobiomodulation therapy combined with static magnetic field is better than placebo in patients with fibromyalgia: a randomized placebo-controlled trial,” 86.67% of subjects treated with FibroLux met success criteria, significantly surpassing the 48.89% success rate in the placebo group.
FibroLux stands at the forefront of innovation in Fibromyalgia treatment, enhancing the quality of life for individuals living with chronic pain.
Multi Radiance Medical has remained dedicated to advancing cutting-edge medical solutions for over 15 years, and FibroLux exemplifies their commitment to providing effective, non-invasive, and clinically proven therapies that empower individuals to reclaim an active and pain-free lifestyle. MRM’s technology has been the subject of 59+ peer-reviewed articles since inception, and the company has actively engaged in over 35 global clinical trials.
